BG
BEAM icon

Bollard Group’s Beam Therapeutics BEAM Stock Holding History

Bollard Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-806
Closed -$65K – 426
2021
Q1 		$65K Hold
806
– – ﹤0.01% 326
2020
Q4 		$66K Hold
806
– – ﹤0.01% 313
2020
Q3 		$20K Hold
806
– – ﹤0.01% 385
2020
Q2 		$23K Buy
+806
New +$17.4K ﹤0.01% 404

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bollard Group's BEAM Position: Q2 2021 in Review

Bollard Group sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 806 shares — an estimated $65K sold.

Bollard Group first reported a position in BEAM in Q2 2020 and held it in 4 quarters. The position peaked at $66K in Q4 2020. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Bollard Group reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bollard Group sold 806 Beam Therapeutics shares in Q2 2021, an estimated $65K.
  • Bollard Group first reported a position in Beam Therapeutics in Q2 2020 and held it in 4 quarters.
  • Bollard Group's Beam Therapeutics position peaked at $66K in Q4 2020.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Bollard Group's 13F filing for Q2 2021, filed 12 Aug 2021.